BACKGROUND: Tenofovir alafenamide fumarate (TAF) co-formulated with elvitegravir (EVG; E), cobicistat (C), and emtricitabine (F), a recommended antiretroviral regimen, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF) as well as neurocognitive (NC) performance change in participants switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF. METHODS: This was a 24-week, single-arm, open-label study in treatment-experienced adults living with human immunodeficiency virus (HIV). Nine participants switched from E/C/F/TDF (150/150/200/300 mg once daily) to E/C/F/TAF (150/150/200/10 mg once daily) at week 12. CSF and total plasma concentrations of EVG, TDF, TAF, tenofovir (TFV), and HIV RNA levels were measured at baseline and week 24. NC performance was estimated by the Montreal Cognitive Assessment. RESULTS: EVG concentrations in CSF and the CSF:plasma ratio remained stable (P = .203) over time. Following the switch, TFV concentrations in CSF and plasma declined (P = .004), although the TFV CSF:plasma ratio increased (P = .004). At week 24, median TAF plasma concentration was 11.05 ng/mL (range, 2.84-147.1 ng/mL) 2 hours postdose but was below assay sensitivity 6 hours after dosing. TAF was below assay sensitivity in all CSF specimens. HIV RNA was ≤40 copies/mL in all CSF and plasma specimens. Three participants (33%) had NC impairment at baseline and 2 (22%) remained impaired at week 24. CONCLUSIONS: Switch to E/C/F/TAF was associated with reductions in TFV concentrations in CSF but stable EVG concentrations that exceeded the 50% inhibitory concentration for wild-type HIV, suggesting that EVG achieves therapeutic concentrations in the central nervous system. No virologic failure or significant NC changes were detected following the switch. CLINICAL TRIALS REGISTRATION: NCT02251236.
BACKGROUND:Tenofovir alafenamide fumarate (TAF) co-formulated with elvitegravir (EVG; E), cobicistat (C), and emtricitabine (F), a recommended antiretroviral regimen, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF) as well as neurocognitive (NC) performance change in participants switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF. METHODS: This was a 24-week, single-arm, open-label study in treatment-experienced adults living with human immunodeficiency virus (HIV). Nine participants switched from E/C/F/TDF (150/150/200/300 mg once daily) to E/C/F/TAF (150/150/200/10 mg once daily) at week 12. CSF and total plasma concentrations of EVG, TDF, TAF, tenofovir (TFV), and HIV RNA levels were measured at baseline and week 24. NC performance was estimated by the Montreal Cognitive Assessment. RESULTS:EVG concentrations in CSF and the CSF:plasma ratio remained stable (P = .203) over time. Following the switch, TFV concentrations in CSF and plasma declined (P = .004), although the TFV CSF:plasma ratio increased (P = .004). At week 24, median TAF plasma concentration was 11.05 ng/mL (range, 2.84-147.1 ng/mL) 2 hours postdose but was below assay sensitivity 6 hours after dosing. TAF was below assay sensitivity in all CSF specimens. HIV RNA was ≤40 copies/mL in all CSF and plasma specimens. Three participants (33%) had NC impairment at baseline and 2 (22%) remained impaired at week 24. CONCLUSIONS: Switch to E/C/F/TAF was associated with reductions in TFV concentrations in CSF but stable EVG concentrations that exceeded the 50% inhibitory concentration for wild-type HIV, suggesting that EVG achieves therapeutic concentrations in the central nervous system. No virologic failure or significant NC changes were detected following the switch. CLINICAL TRIALS REGISTRATION: NCT02251236.
Authors: Andrea Calcagno; Marco Simiele; Ilaria Motta; Simone Mornese Pinna; Roberto Bertucci; Antonio D'Avolio; Giovanni Di Perri; Stefano Bonora Journal: AIDS Res Hum Retroviruses Date: 2016-03-14 Impact factor: 2.205
Authors: Edwin DeJesus; Bernard Haas; Sorana Segal-Maurer; Moti N Ramgopal; Anthony Mills; Nicolas Margot; Ya-Pei Liu; Tariro Makadzange; Scott McCallister Journal: AIDS Res Hum Retroviruses Date: 2018-03-20 Impact factor: 2.205
Authors: Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur Journal: Nat Rev Neurol Date: 2016-03-11 Impact factor: 42.937
Authors: Joel E Gallant; Eric S Daar; François Raffi; Cynthia Brinson; Peter Ruane; Edwin DeJesus; Margaret Johnson; Nathan Clumeck; Olayemi Osiyemi; Doug Ward; Javier Morales-Ramirez; Mingjin Yan; Michael E Abram; Andrew Plummer; Andrew K Cheng; Martin S Rhee Journal: Lancet HIV Date: 2016-03-14 Impact factor: 12.767
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Scott L Letendre; Anthony M Mills; Karen T Tashima; Deborah A Thomas; Sherene S Min; Shuguang Chen; Ivy H Song; Stephen C Piscitelli Journal: Clin Infect Dis Date: 2014-06-18 Impact factor: 9.079
Authors: Davide De Francesco; Xinzhu Wang; Laura Dickinson; Jonathan Underwood; Emmanouil Bagkeris; Daphne S Babalis; Patrick W G Mallon; Frank A Post; Jaime H Vera; Memory Sachikonye; Ian Williams; Saye Khoo; Caroline A Sabin; Alan Winston; Marta Boffito Journal: PLoS One Date: 2021-07-21 Impact factor: 3.240